Liminal BioSciences, Inc.
(NASDAQ : LMNL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.69%68.300.0%$2134.74m
NVAXNovavax, Inc. 7.34%143.0696.5%$1215.67m
SRNESorrento Therapeutics, Inc. -6.19%12.212.8%$753.59m
GILDGilead Sciences, Inc. 0.63%68.611.0%$571.53m
AMGNAmgen, Inc. 0.28%239.521.3%$469.85m
REGNRegeneron Pharmaceuticals, Inc. 0.72%615.302.7%$387.55m
VRTXVertex Pharmaceuticals, Inc. 0.01%267.171.9%$353.19m
BIIBBiogen, Inc. 0.45%289.831.6%$351.67m
BNTXBioNTech SE -2.27%69.390.0%$345.02m
ILMNIllumina, Inc. -2.22%345.693.5%$343.96m
ATNMActinium Pharmaceuticals, Inc. -0.40%9.8713.3%$235.66m
VXRTVaxart, Inc. 0.77%9.160.0%$213.86m
EBSEmergent BioSolutions, Inc. -1.73%132.616.4%$195.97m
MCRBSeres Therapeutics, Inc. -4.32%27.353.6%$178.85m
ALXNAlexion Pharmaceuticals, Inc. 1.23%103.142.0%$165.07m

Company Profile

Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Small Molecule Therapeutics and Plasma-derived Therapeutics. The Small Molecule Therapeutics segment focuses on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including conditions of the lung, liver and kidney. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.